- ALK has reported Health Canada approval for neffy 2 mg, a needle-free nasal spray for the emergency treatment of severe allergic reactions (anaphylaxis) in adults and children weighing 30 kg or more
- The approval introduces a new alternative to traditional epinephrine auto-injectors, addressing a major gap as nearly 2.5M Canadians live with severe allergies and many patients still avoid carrying or using injectable devices during emergencies
- Designed for convenience, neffy fits easily into a pocket, offers a 30-month shelf life, and can tolerate temperatures up to 50°C, helping patients keep emergency treatment accessible wherever they go
- Clinical studies involving more than 700 participants showed that neffy delivered epinephrine rapidly and consistently through the nasal lining, with the product expected to launch across Canada in summer 2026
Takeaways:
Neffy creates a new, needle‑free niche in Canada’s anaphylaxis market that should boost overall epinephrine use and take share from traditional auto‑injectors, especially among patients who avoid needles.
Also, auto‑injector brands will face new competition; payers and hospitals may start revisiting formularies and guidelines to decide when to use sprays versus injections, especially for adults and older children.
Source: CA Newswire
